Phase II Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Cancer Pain- Assessment of Effectiveness, Safety and Pharmacokinetics -

Pain, Intractable Clinical Trial

Official title:
Open Label Study to Confirm Effectiveness, Safety and Pharmacokinetics of Fentanyl Transdermal Matrix Patch, in Japanese Patients With Cancer Pain Who Have Had a Minimum Amount of Morphine Therapy, Such as Equal to Less Than 45 mg/Day of Oral Morphine or Oxycodone Equal to Less Than 30 mg/Day.

Status Completed

Clinical Trial Summary

The purpose of this study is to verify the effectiveness, safety and pharmacokinetics of fentanyl transdermal matrix patches containing either 12.5 mcg/hr, 25 mcg/hr, or 50 mcg/hr in Japanese patients with cancer pain who have been switched from minimum amount of existing morphine preparations, such as equivalent to less than 45 mg/day of oral morphine, or oral oxycodone preparations equivalent to less than 30 mg/day.

Clinical Trial Description

Fentanyl transdermal matrix patch is a narcotic analgesic agent. Compared with the existing reservoir-type Durotep® Patch, it is not liable to leakage of drug solution and does not contain alcohol, which becomes a cause of skin irritation. Also this new formulation becomes available of smaller one of 12.5 mcg/hr while the smallest Durotep® Patch is 25 mcg/hr. This clinical trial was planned to assess effectiveness, safety and pharmacokinetics of fentanyl transdermal matrix patch at an initial transdermal dose of 12.5 mcg in Japanese cancer patients with pain receiving morphine preparations equivalent to less than 45 mg/day of oral morphine (less than 30 mg for suppository, less than 15 mg for injection), oral oxycodone preparations equivalent to less than 30 mg/day, or fentanyl citrate injectable solution equivalent to less than 0.3 mg/day. After pre-treatment period for one to three days for evaluating the eligibility of the patients for the study, patients will use 3 patches for 10 days. Starting from the first day of treatment with 12.5 mcg/hr patch, fentanyl will be applied to the chest, the upper arm or other appropriate site, which will be replaced with a new patch every three days (ca. 72 hr). Total treatment duration is ten days, and dose adjustment can be allowed. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Pain, Intractable

Clinical Trial Details

NCT number	NCT00216658
Study type	Interventional
Source	Janssen Pharmaceutical K.K.
Contact
Status	Completed
Phase	Phase 2
Start date	December 2004
Completion date	September 2005

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03887494` - Study of the Impact of the Femoral Implant "Y-strut" on Lytic Bone Metastases of the Femoral Neck (WAZA-ARY)	N/A
Recruiting	`NCT05761392` - APP-based Precise Management System of Chronic Intractable Pain	N/A
Suspended	`NCT05067257` - Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer	Phase 2
Enrolling by invitation	`NCT02485795` - Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management	N/A
Withdrawn	`NCT01951911` - Effectiveness of Ketamine in Malignant Neuropathic Pain Relief	Phase 3
Completed	`NCT04701008` - Efficacy of Ketamine in Post Anesthesia Recovery Room
Completed	`NCT03350256` - BurstDR™ micrOdosing stimuLation in De-novo Patients	N/A
Completed	`NCT04602286` - How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Pain Sample)	N/A
Completed	`NCT04625504` - Investigating Biological Targets, Markers, and Intervention for Chronic Pain	N/A
Recruiting	`NCT05398003` - Medullary Stimulation for the Treatment of Refractory Neck Pain (S2M)	N/A
Completed	`NCT02886286` - Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain	Phase 4
Completed	`NCT00216684` - Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and Pharmacokinetics	Phase 3
Recruiting	`NCT05775510` - Study to Evaluate Neuromodulation Subject Experience With Contemporary Spinal Cord Stimulation (SCS) Modalities for Chronic Pain
Active, not recruiting	`NCT04727216` - Intermittent vs. Continuous Dorsal Root Ganglion Stimulation	N/A
Completed	`NCT02091076` - Efficacy and Safety of Silk Fibroin With Bioactive Coating Layer Dressing	Phase 1/Phase 2
Completed	`NCT01166906` - Pain Blocking During Drug Administration or Blood Collection With Needles
Recruiting	`NCT04876469` - Radiocontrast Media in the Pulsed Radiofrequency Treatment	N/A
Completed	`NCT05108103` - Determination of Longus Colli Muscle Thickness by Ultrasonography
Completed	`NCT04727749` - Pawsitive Impacts of Therapy Dog Visits	N/A
Completed	`NCT04096391` - Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal Pain Medication (IT) Versus Conventional Medical Management (CMM) in the Non-cancer, Refractory, Chronic Pain Population	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.